Cantor Fitzgerald Weighs in on Organogenesis FY2025 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Organogenesis in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($0.08) for the year. The consensus estimate for Organogenesis’ current full-year earnings is ($0.07) per share.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter last year, the company earned $0.02 EPS.

Organogenesis Stock Up 0.8 %

ORGO stock opened at $3.56 on Thursday. The stock has a market cap of $447.60 million, a P/E ratio of -59.33 and a beta of 1.77. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. Organogenesis has a twelve month low of $2.16 and a twelve month high of $4.57. The company’s 50 day moving average is $3.47 and its two-hundred day moving average is $3.12.

Insider Activity at Organogenesis

In other Organogenesis news, CEO Gary S. Gillheeney sold 18,416 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $3.65, for a total value of $67,218.40. Following the completion of the transaction, the chief executive officer now owns 3,400,778 shares in the company, valued at $12,412,839.70. This represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 278,116 shares of company stock valued at $991,190 in the last ninety days. Insiders own 36.90% of the company’s stock.

Institutional Trading of Organogenesis

Several institutional investors and hedge funds have recently made changes to their positions in ORGO. Captrust Financial Advisors acquired a new position in Organogenesis during the third quarter worth approximately $36,000. Intech Investment Management LLC acquired a new position in shares of Organogenesis in the 3rd quarter valued at $43,000. Pallas Capital Advisors LLC raised its position in Organogenesis by 70.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock valued at $63,000 after purchasing an additional 9,048 shares during the last quarter. Mackenzie Financial Corp boosted its stake in Organogenesis by 46.1% during the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after purchasing an additional 7,678 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Organogenesis during the 3rd quarter worth $72,000. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.